MRCP UK EXAMINATIONS

Detailed explanation-1: -Warfarin competitively inhibits the vitamin K epoxide reductase complex 1 (VKORC1), an essential enzyme for activating the vitamin K available in the body. Through this mechanism, warfarin can deplete functional vitamin K reserves and thereby reduce the synthesis of active clotting factors.

Detailed explanation-2: -Vitamin K antagonists (VKAs) have been the only oral anticoagulants for decades. Among them, warfarin is the most widely used agent, although others such as acenocoumarol, phenprocoumon, and indandione derivatives are also prescribed in some countries.

Detailed explanation-3: -Warfarin is a vitamin K antagonist used to treat venous thromboembolism, pulmonary embolism, thromboembolism with atrial fibrillation, thromboembolism with cardiac valve replacement, and thromboembolic events post myocardial infarction.

Detailed explanation-4: -Warfarin and other vitamin K antagonists (VKAs, also called coumarins; eg, acenocoumarol, phenprocoumon, fluindione) are used in a variety of clinical settings.